MetaVia (MTVA) announced positive top-line 16-week results from the two-part Phase 2a clinical trial in patients with presumed metabolic dysfunction-associated steatohepatitis, or MASH.

Q32 Bio (QTTB) announced topline results from the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart, or ADX-914, which identified encouraging clinical activity in patients ...

Bioxodes enrolls patients in phase 2a clinical trial of BIOX-101 in intracerebral hemorrhagic stroke: Gosselies, Belgium Saturday, December 21, 2024, 15:00 Hrs [IST] Bioxodes SA, ...

Centessa Pharmaceuticals, founded from the merger of 10 biotech companies, is based on an asset-centric model, primarily ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

(RTTNews) - MetaVia Inc. (MTVA), Wednesday announced positive 16-week results from the two-part Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks InflaRx ( (IFRX) ) has issued an update.

Each of the two parts of the Phase 2a trial of DA-1241 were designed ... For more information on this clinical trial, please visit: www.clinicaltrials.gov NCT06054815. About DA-1241 DA-1241 ...

MIRA Pharmaceuticals submits an IND for Ketamir-2, aiming to treat neuropathic pain with 100% pain reversal shown in ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Compelling Results for DA-1241 in Phase 2a MASH Trial On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from ...

Along with the potential to achieve improved patient health outcomes, results from the phase 2a trials with TRP-8802 will ...

Completing treatment of first cohort of patients will trigger interim analysisBIOX-101 is a first-in-class drug candidate, a peptide developed from tick saliva Gosselies (Belgium), 19 2024 (08:30 CET) ...